CorMedix Inc. (CRMD) Stock Analysis

CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position

Mon, November 2, 2026 at 1:39 PM UTC 2 min read

CorMedix Therapeutics (NASDAQ:CRMD) has reaffirmed its revenue guidance for 2026, expecting between $325 million and $345 million, while reporting an unaudited cash position of approximately $355 million as of September 30, 2026. The company also highlighted a significant increase in Medicare reimbursement for its product DefenCath, with a new add-on payment of $8.32 per dialysis session for the first quarter of 2027, which is substantially higher than the current rate. Further financial details will be provided during the upcoming earnings call on November 12.

Read full article →

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Thu, October 8, 2026 at 2:40 PM UTC 2 min read

CRMD and PRTA are being compared as potential investments for value investors, with analysts evaluating their financial health and growth prospects. This analysis is significant as it helps investors identify which stock may offer better long-term value and returns. As market conditions fluctuate, understanding the strengths and weaknesses of these companies can guide investment decisions and optimize portfolio performance.

Read full article →